Healthy Living/WellnessAstraZeneca Lupus Drug Anifrolumab Impresses In Mid-Stage Trial AstraZeneca's anifrolumab targets inflammation-related protein called type 1 interferon (IFN) receptor, which plays a central role in lupus. Phase II testing showed promising results.by Katherine Derla
Healthy Living/WellnessGout Drug Lesinurad By AstraZeneca Receives Approval Recommendation From FDA Advisory Committeeby Dianne Depra
Healthy Living/WellnessFDA Gives AstraZeneca Brilinta Nod Of Approval For Longer-Term Useby Dianne Depra
Healthy Living/WellnessAstraZeneca To Pay Inovio $727.5 Million For Experimental Cancer Drugby Rhodi Lee
Healthy Living/WellnessAstraZeneca-Lilly Collaboration To Test New Combination Of Cancer Drugsby Dianne Depra
Healthy Living/WellnessAstraZeneca Heart Drug Brilinta May Benefit Heart Patients But Carries Risksby James Maynard
Healthy Living/WellnessFDA approves AstraZeneca's EPANOVA, adjunct to diet for people with very high triglyceride levelsby Anne Francis